D-0354-2025 Class II Ongoing

Recalled by Somerset Therapeutics Private Limited — Bengaluru, N/A

FDA drug recall D-0354-2025 was initiated by Somerset Therapeutics Private Limited on Mar 21, 2025 and is designated Class II. Reason for recall: Lack of Assurance of Sterility: Media fill with bacterial contamination The recall status is ongoing. Affected quantity: 506,080 vials.

Recall details

Product Type
Drugs
Report Date
Apr 16, 2025
Initiation Date
Mar 21, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
506,080 vials

Product description

Methocarbamol Injection USP 1,000 mg/10 mL (100 mg/mL), 10 mL Single Dose Vial, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Somerset, NJ 08873, NDC 70069-101-25 (immediate carton) and 70069-101-05 (5x10 mL carton)

Reason for recall

Lack of Assurance of Sterility: Media fill with bacterial contamination

Distribution pattern

U.S. Nationwide

Code information

NDC 70069-101-25; A240304, A240305, A240320, A240322, A240334, A240335, A240340, exp. date 05/2026; A240342, A240347, A240385, A240391, exp. date 06/2026; NDC 70069-101-05; A240326, exp. date 05/2026

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0354-2025
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0354-2025. Report a data issue: hello@regdatalab.com.